Gentamicin, tobramycin, amikacin, and netilmicin levels in tears following intravenous administration.
Peak and trough tear and serum concentrations were determined in 27 human volunteers undergoing intravenous (IV) gentamicin sulfate, tobramycin sulfate, amikacin sulfate, and netilmicin sulfate therapy. Although effective serum concentrations were achieved, tear levels were subtherapeutic. The mean peak tear concentrations were 0.4 microgram/mL, 0.5 microgram/mL, 1.7 micrograms/mL, and 0.3 microgram/mL for gentamicin, tobramycin, amikacin, and netilmicin, respectively. These levels did not approach the minimum inhibitory concentrations for Pseudomonas and raise some concern regarding the risk-benefit ratio of IV antibiotics for bacterial keratitis.
D000328:Adult; D000368:Aged; D000583:Amikacin / Q000008:administration & dosage / Q000032:analysis* / Q000378:metabolism; D001424:Bacterial Infections / Q000188:drug therapy; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage / Q000032:analysis* / Q000378:metabolism; D006801:Humans; D007263:Infusions, Parenteral; D007612:Kanamycin / Q000031:analogs & derivatives*; D007634:Keratitis / Q000188:drug therapy; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009428:Netilmicin / Q000008:administration & dosage / Q000032:analysis* / Q000378:metabolism; D013666:Tears / Q000032:analysis* / Q000378:metabolism; D014031:Tobramycin / Q000008:administration & dosage / Q000032:analysis* / Q000378:metabolism
D005839:Gentamicins; D009428:Netilmicin; D007612:Kanamycin; D000583:Amikacin; D014031:Tobramycin